標(biāo)題: Titlebook: Coronary Artery Disease: Therapeutics and Drug Discovery; Miao Wang Book 2020 Springer Nature Singapore Pte Ltd. 2020 coronary artery dise [打印本頁] 作者: controllers 時間: 2025-3-21 17:06
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery影響因子(影響力)
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery影響因子(影響力)學(xué)科排名
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery網(wǎng)絡(luò)公開度
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery被引頻次
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery被引頻次學(xué)科排名
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery年度引用
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery年度引用學(xué)科排名
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery讀者反饋
書目名稱Coronary Artery Disease: Therapeutics and Drug Discovery讀者反饋學(xué)科排名
作者: Heretical 時間: 2025-3-21 23:44
Evidence in Guidelines for Treatment of Coronary Artery Disease,is discussed, which plays an important role in CAD risk control, including forming healthy dietary pattern, maintaining proper body weight, physical exercise, smoking cessation, and so on. Part 2 elaborated on revascularization strategies and medical treatments in patients presenting with acute coro作者: BOLT 時間: 2025-3-22 01:21
Revascularization for Coronary Artery Disease: Principle and Challenges,r coronary revascularization and discusses the evidence on the mechanisms, indications, techniques, and outcomes of these approaches. Targeting coronary thrombus, fibrinolysis is indicated for patients with diagnosed myocardial infarction and without high risk of severe hemorrhage. The development o作者: armistice 時間: 2025-3-22 07:10 作者: labyrinth 時間: 2025-3-22 09:37
Lipid-Modifying Drugs: Pharmacology and Perspectives,r atherosclerosis and CAD, which results in cardiac ischemic injury and myocardial infarction. Lipid-modifying drugs can effectively improve lipid abnormalities including reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) or increasing high-density lipoprotein cholesterol (H作者: 襲擊 時間: 2025-3-22 13:31 作者: 襲擊 時間: 2025-3-22 19:12
Pharmaceutical Treatment for Heart Failure, Currently, HF is divided into three groups which include HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with midrange EF (HFmrEF). Even though major advances have been made in treating HFrEF during the past decades, heart failure is a fatal disease. In作者: 惡名聲 時間: 2025-3-22 22:59
Drug Discovery for Coronary Artery Disease,recently approved PCSK9 inhibitors, together with antithrombotic drugs have been historically successful in reducing the occurrence of coronary artery disease (CAD), the high incidence of CAD remains imposing the largest disease burden on our healthcare systems. We reviewed cardiovascular drugs rece作者: reception 時間: 2025-3-23 02:22
Book 2020ts and thrombolysis. This chapter also addresses the main therapeutic challenges..The following chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure cons作者: fibula 時間: 2025-3-23 08:12
Coronary Artery Disease: Therapeutics and Drug Discovery作者: DUCE 時間: 2025-3-23 10:53 作者: nocturnal 時間: 2025-3-23 16:06 作者: 民間傳說 時間: 2025-3-23 21:22
Revascularization for Coronary Artery Disease: Principle and Challenges,rtant determinants of patient outcomes. Multidisciplinary decision-making should analyze current evidence, considering the clinical condition of patients, and determine the safety and necessity for coronary revascularization with either PCI or CABG. For coronary artery disease with more complex lesi作者: Ostrich 時間: 2025-3-24 01:08
Drug Discovery for Coronary Artery Disease,ing atherothrombosis opens a new era of therapeutic discovery that targets inflammation. Chinese traditional medicine and cardiac regeneration are also discussed. Human genetics studies of CAD and further delineation of key determinants/pathways underlying the residual risk of CAD under current stan作者: PLAYS 時間: 2025-3-24 04:24 作者: delusion 時間: 2025-3-24 06:57
Welcome Address by the Conference Chairmant patients. While cumulating studies have focused on optimizing pharmacological therapy (referring to nitrates, beta-blockers, calcium channel blockers, antiplatelet agents, ACEI/ARB, statins, etc.), education, habitual modification, and social support matters a lot for reducing cardiac morbidity an作者: 蘑菇 時間: 2025-3-24 14:08
G. F. Bennett,E. C. Greiner,W. Threlfallrtant determinants of patient outcomes. Multidisciplinary decision-making should analyze current evidence, considering the clinical condition of patients, and determine the safety and necessity for coronary revascularization with either PCI or CABG. For coronary artery disease with more complex lesi作者: spondylosis 時間: 2025-3-24 15:23 作者: 使苦惱 時間: 2025-3-24 19:25
0065-2598 owing chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure cons978-981-15-2519-3978-981-15-2517-9Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: delegate 時間: 2025-3-25 00:55 作者: voluble 時間: 2025-3-25 04:36
Malnutrition in Captive Birds of Preyure as well as those that prevent heart failure progression, in each category major clinical trials are also described. In addition, information about some of potential new drugs are also mentioned. Traditional Chinese medicine also shows its potential in treating HF, and we are still lack of medicine to treat HFpEF.作者: mitten 時間: 2025-3-25 09:48 作者: engagement 時間: 2025-3-25 11:59
Pharmaceutical Treatment for Heart Failure,ure as well as those that prevent heart failure progression, in each category major clinical trials are also described. In addition, information about some of potential new drugs are also mentioned. Traditional Chinese medicine also shows its potential in treating HF, and we are still lack of medicine to treat HFpEF.作者: 證實(shí) 時間: 2025-3-25 18:24
Book 2020e. It highlights drug pharmacology and therapeutic challenges, with a special emphasis on the underlying principles of available therapeutics and the on-going development of drugs for coronary artery disease..The book is divided into eight chapters, the first of which describes the classical mechani作者: harrow 時間: 2025-3-25 21:55 作者: TERRA 時間: 2025-3-26 02:00
A. Aeschlimann,C. Mermod,J. F. Graf need. In this chapter, we provide an overview on the pathophysiology of thrombosis, followed by introduction of each class of antithrombotic drugs including their pharmacology, clinical applications and limitations. Practical challenges and future perspectives of antithrombotic drugs are discussed in the last part of this chapter.作者: BACLE 時間: 2025-3-26 06:00 作者: 信徒 時間: 2025-3-26 09:56 作者: 事先無準(zhǔn)備 時間: 2025-3-26 13:55 作者: cacophony 時間: 2025-3-26 18:54 作者: 熔巖 時間: 2025-3-26 21:00 作者: ARBOR 時間: 2025-3-27 02:15
978-981-15-2519-3Springer Nature Singapore Pte Ltd. 2020作者: 高貴領(lǐng)導(dǎo) 時間: 2025-3-27 07:03
Miao WangProviding a cutting-edge understanding of the mechanisms of coronary artery disease (CAD).Highlighting the drug pharmacology and therapeutic challenges to treat CAD.Emphasizing the development for CAD作者: 殺蟲劑 時間: 2025-3-27 10:36 作者: 獨(dú)裁政府 時間: 2025-3-27 16:39 作者: 使殘廢 時間: 2025-3-27 19:30
Welcome Address by the Conference Chairmanis discussed, which plays an important role in CAD risk control, including forming healthy dietary pattern, maintaining proper body weight, physical exercise, smoking cessation, and so on. Part 2 elaborated on revascularization strategies and medical treatments in patients presenting with acute coro作者: hermitage 時間: 2025-3-28 01:31 作者: COKE 時間: 2025-3-28 05:01 作者: 煩擾 時間: 2025-3-28 08:42
Malnutrition in Captive Birds of Preyr atherosclerosis and CAD, which results in cardiac ischemic injury and myocardial infarction. Lipid-modifying drugs can effectively improve lipid abnormalities including reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) or increasing high-density lipoprotein cholesterol (H作者: Cleave 時間: 2025-3-28 13:33 作者: Mendacious 時間: 2025-3-28 17:09 作者: 蘆筍 時間: 2025-3-28 22:41 作者: IDEAS 時間: 2025-3-29 00:35
